Considering cyanobacterial cyclopeptides as potential novel targeted anticancer therapeutics, we focus on developing microcystin analogues optimized to efficiently target OATP-expressing metastatic cancers that are resistant to conventional chemotherapy. The gene discussed is SLCO1A2; the disease is metastatic malignant neoplasm.